This webinar will review the molecular basis for the different types of targeted therapy, including immunotherapy, for periocular and orbital tumors. Through understanding the molecular basis, the mechanism for resistance and side effects with this class of medication will become clear. We will discuss the possible future use for targeted therapy and what some of the current limitations in neoadjuvant or adjuvant use are. Specifically, this will include the issues with margin control with neoadjuvant use of hedgehog inhibition. Lecturer: Dr. Vivian Yin, Memorial Sloan Kettering Cancer Center, New York, USA
0 Comments